Large-scale deep proteomic analysis in Alzheimer's disease brain regions across race and ethnicity.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Seifar Fatemeh, Fox Edward J, Shantaraman Anantharaman, Liu Yue, Dammer Eric B, Modeste Erica, Duong Duc M, Yin Luming, Trautwig Adam N, Guo Qi, Xu Kaiming, Ping Lingyan, Reddy Joseph S, Allen Mariet, Quicksall Zachary, Heath Laura, Scanlan Jo, Wang Erming, Wang Minghui, Linden Abby Vander, Poehlman William, Chen Xianfeng, Baheti Saurabh, Ho Charlotte, Nguyen Thuy, Yepez Geovanna, Mitchell Adriana O, Oatman Stephanie R, Wang Xue, Carrasquillo Minerva M, Runnels Alexi, Beach Thomas, Serrano Geidy E, Dickson Dennis W, Lee Edward B, Golde Todd E, Prokop Stefan, Barnes Lisa L, Zhang Bin, Haroutunian Varham, Gearing Marla, Lah James J, De Jager Philip, Bennett David A, Greenwood Anna, Ertekin-Taner Nilüfer, Levey Allan I, Wingo Aliza, Wingo Thomas, Seyfried Nicholas T
Аннотация
METHODS: Two cortical regions, from multiple centers, were harmonized by uniform neuropathological diagnosis. Among 998 unique donors, 273 donors self-identified as African American, 229 as Latino American, and 434 as NHW.
RESULTS: While amyloid precursor protein and the microtubule-associated protein tau demonstrated higher abundance in AD brains, no significant race-related differences were observed. Further proteome-wide and focused analyses (specific amyloid beta [Aβ] species and the tau domains) supported the absence of racial differences in these AD pathologies within the brain proteome.
DISCUSSION: Our findings indicate that the racial differences in AD risk and clinical presentation are not underpinned by dramatically divergent patterns in the brain proteome, suggesting that other determinants account for these clinical disparities.
HIGHLIGHTS: We present a large-scale proteome (∼10,000 proteins) of DLPFC (998) and STG (244) across AD cases. About 50% of samples were from racially and ethnically diverse brain donors. Key AD proteins (amyloid and tau) correlated with CERAD and Braak stages. No significant race-related differences in amyloid and tau protein levels were observed in AD brains. AD-associated protein changes showed a strong correlation between the brain proteomes of African American and White individuals. This dataset advances understanding of ethnoracial-specific AD pathways and potential therapies.